Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

ИЗУЧЕНИЕ ВОЗМОЖНОСТЕЙ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ГЕПАТИТА С ТРАНСПЛАНТАТА ПЕЧЕНИ

https://doi.org/10.15825/1995-1191-2011-1-17-26

Полный текст:

Аннотация

Обобщен собственный опыт противовирусной терапии возвратной инфекции HCV после транспланта- ции печени. С 2002 по 2010 гг. 19 пациентов получили 22 курса лечения пегилированными интерфе- ронами и рибавирином. Стойкий вирусологический ответ составил 25% при анализе в зависимости от назначенного лечения и 40% при анализе per protocol. Применение факторов роста позволило уменьшить частоту снижения доз противовирусных препаратов и перерывов в терапии. Авторы обращают внимание на медленную раннюю вирусную кинетику в изученной группе больных, что обосновывает увеличение продолжительности противовирусной терапии более 48 недель. 

Об авторах

В. Е. Сюткин
Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского, Москва
Россия


О. И. Андрейцева
Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского, Москва
Россия


А. В. Чжао
Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского, Москва Кафедра трансплантологии и искусственных органов МГМСУ
Россия


Список литературы

1. Сюткин В.Е. Стратегия лечения больных хрониче- ским гепатитом C на современном этапе // Клиниче- ская фармакология и терапия. 2008. Т. 17 (2). С. 16–19.

2. Сюткин В.Е. Новые возможности повышения эф- фективности противовирусной терапии больных хроническим гепатитом С // Инфекционные болезни. 2009. Т. 7. No 2. С. 55–59.

3. Adeyemi O.M. Hepatitis C in HIV-positive patients— treatment and liver disease outcomes // J Clin Gastroen- terol. 2007. Vol. 41. P. 75–87

4. Alter H.J., Seeff L.B. Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000. Vol. 20. P. 17–35.

5. Bahra M., Neumann U.P., Jacob D. et al. Fibrosis pro- gression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy) // Transplantation. 2007. Vol. 83. P. 351–353.

6. Berenguer M. Systematic review of the treatment of es- tablished recurrent hepatitis C with pegylated interferon in combination with ribavirin // J Hepatol. 2008. Vol. 49. P. 274–287.

7. Berenguer M., Palau A., Fernandez A. et al. Efficacy, pre- dictors of response, and potential risks associated with an- tiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2006. Vol. 12. P. 1067–1076.

8. Berenguer M., Prieto M., Rayon J.M. et al. Natural his- tory of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000. 32. P. 852–858.

9. Bizollon T., Pradat P., Mabrut J.Y. et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with re- current chronic hepatitis C // Am. J. Transplant. 2005. Vol. 5. P. 1909–1913.

10. Castells L., Vargas V., Allende H. et al. Combined treat- ment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation // J. Hepatol. 2005. Vol. 43. P. 53–59.

11. Chalasani N., Manzarbeitia C., Ferenci P. et al. Pegin- terferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trial (published erratum ap- pears in Hepatology 2005. Vol. 42. P. 506). Hepatology. 2005. Vol. 41. P. 289–298.

12. Donato M., Agnelli F., Rigamonti C.et al. Might Rapid Virological Response Be Used as a Stopping Rule in Liver Transplant Recipients Treated with Pegylated In- terferon Plus Ribavirin? Liver transplantation. 2008. Vol. 14. P. 1383–1384

13. Dumortier J., Scoazec J.Y., Chevallier P. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinati- on // J. Hepatol 2004. Vol. 40. P. 669–674.

14. Fried M., Shiffman M., Reddy K. et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infec- tion. N. Engl. J. Med. 2002. Vol. 347. P. 975–982.

15. Gane E.J., Naoumov N.V., Qian K.P. et al. A longitudi- nal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996. Vol. 110. P. 167–177.

16. Gish R.G., Afdhal N.H., Dieterich D.T., Reddy KR. Man- agement of hepatitis C virus in special populations: pa- tient and treatment considerations. Clin Gastroenterol Hepatol. 2005. Vol. 3. P. 311–318.

17. Gurusamy K.S., Tsochatzis E., Xirouchakis E. et al. An- tiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010. Vol. 20 (1). CD006803. Review.

18. HanounehI.A., Miller C., Aucejo F. et al. Recurrent hepa- titis C after liver transplantation: on treatment prediction of response to peginterferon/ribavirin therapy // Liver Transpl. 2008. Vol. 14. P. 53–58.

19. Ikegami T., Taketomi A., Soejima Y. et al. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hep- atitis C // Transplant Proc. 2009. Vol. 41 (10). P. 4246– 4252.

20. Lilly L., Selzner N., Therapondos G. et al. Improved sur- vival in liver transplant recipients (LT) treated for recur- rent hepatitis C (HCV) is seen in both relapsers and in sustained responders. Paper presented at: 2008 American Transplant Congress; May 31–June 4, 2008. Toronto, Canada.

21. Manns M., McHutchison J., Gordon S. et al. Peginterfe- ron alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001. Vol. 358. P. 958–965.

22. Moeller M., Divine G., Brown K.A. Impact of length of therapy and predictive value models on SVR in HCV pa- tients post OLT. Hepatology. 2009. Vol. 50. 391A.

23. Oton E., Barcena R., Moreno-Planas J.M. et al. Hepa- titis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ri- bavirin. Am. J. Transplant. 2006. Vol. 6. P. 2348–2355.

24. Picciotto F.P.,Tritto G., Lanza A.G. et al. Sustained viro- logical response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation // J. Hepatol. 2007. Vol. 46. P. 459–465

25. Roche B. and Samuel D. Aspects of hepatitis C virus in- fection relating to liver transplantation. Eur. J. Gastroen- terol Hepatol. 2005. Vol. 18. P. 313–320.

26. Samuel D., Bizollon T., Feray C. et al. Interferon-a2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterol- ogy. 2003. Vol. 124. P. 642–650.

27. Schmidt S.C., Bahra M., Bayraktar S. et al. Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon. Dig Dis. Sci. 2010. Vol. 55 (7). P. 2063–2069.

28. Sheiner P.A., Boros P., Klion F.M. et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998. Vol. 28. P. 831–838.

29. Terrault N.A., Berenguer M. Treating hepatitis C infec- tion in liver transplant recipients. Liver Transpl. 2006. Vol. /12. P. 1192–1204.

30. Torriani F.J., Ribeiro R.M., Gilbert T.L. et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)

31. dynamics during HCV treatment in HCV/HIV coinfec-

32. tion // J. Infect. Dis. 2003. Vol. 188. P. 1498–1507.

33. Ueda Y., Takada Y., Haga H. et al. Limited benefit of bio- chemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver trans-

34. plantation. Transplantation. 2008. Vol. 85. P. 855–862.

35. Veldt B.J., Poterucha J.J., Watt K.D.S. et al. Impact of pegylated interferon and ribavirin treatment on graft sur- vival in liver transplant patients with recurrent hepatitis C infection // Am. J. Transpl. 2008. Vol. 8. P. 2426–2433.

36. Walter T., Scoazec J.Y., Guillaud O. et al. Long-term anti- viral therapy for recurrent hepatitis C after liver transplan- tation in nonresponders: biochemical, virological, and his-

37. tological impact. Liver Transpl. 2009. Vol. 15. P. 54–63.

38. Wang C.S., Ko H.H., Yoshida E.M. et al. Interferon- based combination anti-viral therapy for hepatitis C vi- rus after liver transplantation: a review and quantitative analysis // Am. J. Transplant. 2006. Vol. 6. P. 1586–1599.

39. Xirouchakis E., Triantos C., Manousou P. et al. Pegyla- ted-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies //

40. Journal of Viral Hepatitis. 2008. Vol. 15. P. 699–709.

41. Zimmermann T., Bocher W.O., Biesterfeld S. et al. Ef- ficacy of an escalating dose regimen of pegylated inter- feron alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007.

42. Vol. 20. P. 583–590.


Для цитирования:


Сюткин В.Е., Андрейцева О.И., Чжао А.В. ИЗУЧЕНИЕ ВОЗМОЖНОСТЕЙ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ГЕПАТИТА С ТРАНСПЛАНТАТА ПЕЧЕНИ. Вестник трансплантологии и искусственных органов. 2011;13(1):17-26. https://doi.org/10.15825/1995-1191-2011-1-17-26

For citation:


Syutkin V.E., Andreytzeva O.I., Chzhao A.V. POSSIBILITIES OF HEPATITIS C ANTIVIRAL TREATMENT IN LIVER TRANSPLANT RECIPIENTS. Russian Journal of Transplantology and Artificial Organs. 2011;13(1):17-26. (In Russ.) https://doi.org/10.15825/1995-1191-2011-1-17-26

Просмотров: 265


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)